<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1581">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745104</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1707-I-101-AUS</org_study_id>
    <nct_id>NCT04745104</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous Administration of SHR-1707 in Healthy Young Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atridia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atridia Pty Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, single dose escalation phase 1 study to&#xD;
      access the Pharmacokinetics and Pharmacodynamics of Single Intravenous Administration of&#xD;
      SHR-1707&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of two parts: Subjects will be randomized to receive SHR-1707 as&#xD;
      reflected by the guiding principle for the dose esclation/expansion phase. Each dose group&#xD;
      includes a screening period, a baseline period, an observational period, and a safety&#xD;
      follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Actual">March 21, 2022</completion_date>
  <primary_completion_date type="Actual">March 21, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Start of Treatment to end of study (approximately 12 weeks)</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-last</measure>
    <time_frame>Start of Treatment to end of study (approximately 12 weeks)</time_frame>
    <description>Area under the concentration-time curve from time 0 to last time point after SHR-1707 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-inf</measure>
    <time_frame>Start of Treatment to end of study (approximately 12 weeks)</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity after SHR-1707 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Tmax</measure>
    <time_frame>Start of Treatment to end of study (approximately 12 weeks)</time_frame>
    <description>Time to Cmax of SHR-1707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Start of Treatment to end of study (approximately 12 weeks)</time_frame>
    <description>Maximum observed concentration of SHR-1707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-CL/F</measure>
    <time_frame>Start of Treatment to end of study (approximately 12 weeks)</time_frame>
    <description>Apparent clearance of SHR-1707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Vz/F</measure>
    <time_frame>Start of Treatment to end of study (approximately 12 weeks)</time_frame>
    <description>Apparent volume of distribution during terminal phase of SHR-1707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-t1/2</measure>
    <time_frame>Start of Treatment to end of study (approximately 12 weeks)</time_frame>
    <description>Terminal elimination half-life of SHR-1707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics MRT</measure>
    <time_frame>Start of Treatment to end of study (approximately 12 weeks)</time_frame>
    <description>Mean residence time of SHR-1707</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Start of Treatment to end of study (approximately 12 weeks)</time_frame>
    <description>Change from baseline of plasma biomarker concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug antibody</measure>
    <time_frame>Start of Treatment to end of study (approximately 12 weeks)</time_frame>
    <description>The percentage of subjects with positive ADA titers over time for SHR-1707.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>SHR-1707 Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1707 or placebo is administered intravenous to young healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1707 Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1707 or placebo is administered intravenous to young healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1707 Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1707 or placebo is administered intravenous to young healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1707 Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1707 or placebo is administered intravenous to young healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1707 Dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1707 or placebo is administered intravenous to young healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1707 Dose level 3 (Elderly subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1707 or placebo is administered intravenous to Elderly subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1707</intervention_name>
    <description>SHR-1707 will be administered through IV infusion</description>
    <arm_group_label>SHR-1707 Dose level 1</arm_group_label>
    <arm_group_label>SHR-1707 Dose level 2</arm_group_label>
    <arm_group_label>SHR-1707 Dose level 3</arm_group_label>
    <arm_group_label>SHR-1707 Dose level 3 (Elderly subjects)</arm_group_label>
    <arm_group_label>SHR-1707 Dose level 4</arm_group_label>
    <arm_group_label>SHR-1707 Dose level 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered through IV infusion</description>
    <arm_group_label>SHR-1707 Dose level 1</arm_group_label>
    <arm_group_label>SHR-1707 Dose level 2</arm_group_label>
    <arm_group_label>SHR-1707 Dose level 3</arm_group_label>
    <arm_group_label>SHR-1707 Dose level 3 (Elderly subjects)</arm_group_label>
    <arm_group_label>SHR-1707 Dose level 4</arm_group_label>
    <arm_group_label>SHR-1707 Dose level 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand the trial procedures and possible adverse events, voluntarily&#xD;
             participate in the trial,&#xD;
&#xD;
          2. Male or female aged between 18 years and 45 years (inclusive) at the date of signed&#xD;
             consent form in Part 1 and aged between 55 years and 80 years (inclusive) in Part 2&#xD;
&#xD;
          3. Total body weight of 45~100 kg (inclusive), with a body mass index (BMI) of 19~32&#xD;
             kg/m2 (inclusive) at screening and baseline&#xD;
&#xD;
          4. Subjects with good general health, no clinically significant abnormalities, or have&#xD;
             underlying disease which is believed to have minimal impact on the study treatment in&#xD;
             elderly subjects&#xD;
&#xD;
          5. WOCBP agree to take effective contraceptive methods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe injuries or surgeries within 6 months before screening&#xD;
&#xD;
          2. ALT, or AST or total bilirubin level &lt;1.5x upper limit of normal range (ULN) at&#xD;
             screening or baseline visits&#xD;
&#xD;
          3. QTcF &gt; 450msec (Male), QTcF &gt; 470msec (Female) in 12-lead ECG test during screening&#xD;
             and baseline&#xD;
&#xD;
          4. Known history or suspected of being allergic to the study drug.&#xD;
&#xD;
          5. Use of any medicine within 14 days (including any prescription, or over-the-counter&#xD;
             medicine, herbal remedy or nutritional supplement, except for vitamins and&#xD;
             acetaminophen with recommended dose [The dose of acetaminophen should be less than&#xD;
             2g/day, and no more than 3 days for continuous use]), or within 5 half-lives&#xD;
&#xD;
          6. Live (attenuated) vaccination within 1 month before screening&#xD;
&#xD;
          7. Blood donation or loss of more than 400 mL of blood within 3 months; or received blood&#xD;
             transfusion within 3 months before screening.&#xD;
&#xD;
          8. History of alcohol abuse in the past 12 months of screening&#xD;
&#xD;
          9. History of illicit or prescription drug abuse or addiction within 12 months of&#xD;
             screening&#xD;
&#xD;
         10. More than 5 cigarettes daily for 12 months before screening&#xD;
&#xD;
         11. Participation in clinical trials of other investigational drugs (include placebo) or&#xD;
             medical devices within 3 months prior to screening&#xD;
&#xD;
         12. Researchers and relevant staff of the research center or other persons directly&#xD;
             involved in the implementation of the program&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Atridia Pty Limited</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>July 11, 2022</last_update_submitted>
  <last_update_submitted_qc>July 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

